Completed PHASE2 INTERVENTIONAL NCT00014352

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Phase II Trial Of Sequential Estramustine/Paclitaxel Followed By Doxorubicin/Ketoconazole In Patients With Androgen-Independent Prostate Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Prostate Cancer Thromboembolism

Interventions docetaxel doxorubicin hydrochloride estramustine phosphate sodium ketoconazole warfarin

Updated 5 times since 2017 Last updated: Jan 15, 2013 Started: Sep 30, 2000 Primary completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prostate Cancer and Thromboembolism and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States